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Abstract
Carbonyl reduction constitutes a phase I reaction for many xenobiotics and is carried out in mammals mainly by members
of two protein families, namely aldo-keto reductases and short-chain dehydrogenases/reductases. In addition to their
capacity to reduce xenobiotics, several of the enzymes act on endogenous compounds such as steroids or eicosanoids. One
of the major carbonyl reducing enzymes found in humans is carbonyl reductase 1 (CBR1) with a very broad substrate
spectrum. A paralog, carbonyl reductase 3 (CBR3) has about 70% sequence identity and has not been sufficiently
characterized to date. Screening of a focused xenobiotic compound library revealed that CBR3 has narrower substrate
specificity and acts on several orthoquinones, as well as isatin or the anticancer drug oracin. To further investigate structure-
activity relationships between these enzymes we crystallized CBR3, performed substrate docking, site-directed mutagenesis
and compared its kinetic features to CBR1. Despite high sequence similarities, the active sites differ in shape and surface
properties. The data reveal that the differences in substrate specificity are largely due to a short segment of a substrate
binding loop comprising critical residues Trp229/Pro230, Ala235/Asp236 as well as part of the active site formed by Met141/
Gln142 in CBR1 and CBR3, respectively. The data suggest a minor role in xenobiotic metabolism for CBR3.
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Introduction
Reduction of carbonyl groups to the corresponding alcohols
constitutes a significant metabolic step both for endogenous and
xenobiotic compounds [1–3]. These reactions are carried out by
distinct NAD(P)(H) dependent oxidoreductases mainly belonging
to three protein superfamilies, namely the short-chain dehydroge-
nases/reductases (SDR), aldo-keto-reductases (AKR), or medium-
chain dehydrogenases/reductases (MDR) [1–3].
A unifying feature of carbonyl reductases appears to be their
broad and often overlapping substrate specificity. Endogenous
substrates comprise steroids, eicosanoids, cofactors, neurotrans-
mitters and polyols. In addition, a large set of xenobiotics has
been identified as substrates for carbonyl reducing enzymes
including drugs such as warfarin, daunorubicin or ketoprofen,
environmental pollutants (PAH quinones derived from diesel
exhaust such as phenanthrenequinone) or tobacco derived
carcinogens like NNK [2,3].
In humans, several enzymes contribute significantly to the
metabolic reductive transformation, mainly found in tissues such
as liver, kidney, placenta or the central nervous system. The major
cytosolic enzymes identified are the NADPH-dependent carbonyl
reductase (CBR1, according to the official nomenclature system
SDR21C1)[4,5], belonging to the SDR family, and members of
the AKR family such as aldehyde reductase (AKR1A1), aldose
reductase (AKR1B1), several dihydrodiol/hydroxysteroid dehy-
drogenases (of the AKR1C subfamily) or aflatoxin aldehyde
reductase (AKR7A2) [1–3,6].
CBR1 fulfills an important role in the phase I metabolism of
xenobiotics. Substrates include o-quinones derived from polycyclic
aromatic hydrocarbons (PAH) or p-quinones such as menadione,
besides an extraordinarily wide spectrum of xenobiotic carbonyls
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trosamino-1-(3-pyridyl)-1-butanone. The endogenous compound
spectrum comprises steroids, eicosanoids and lipid derived
aldehydes [7–9].
Recent studies indicate a role for CBR1 in apoptosis, tumor
metastasis and oxygen induced stress [10–12]. At present, no clear
evidence is available which specific endogenous substrate is
responsible for these effects, however a recent study showed that
CBR1 effectively inactivates in vitro the lipid aldehyde 4-
oxononenal [13], indicating that CBR1 is involved in the stress
response and elimination of metabolites produced by reactive
oxygen species.
A human paralog, CBR3 (SDR21C2)[4,5], which is 71%
identical to CBR1 [6] is located in the vicinity of the CBR1 gene
on chromosome 21 at 21q22.12. However, thus far limited
information on enzymatic properties of CBR3 is available [14]; in
this and another study [15] only CBR3 activity towards the model
substrate menadione, 4-nitrobenzaldehyde or 4-benzoylpyridine
was reported. Given the importance of CBR1 and other carbonyl
reductases in endogenous and xenobiotic carbonyl metabolism, we
performed a study to establish a substrate specificity profile of
human CBR3. To understand structure-function relationships
between the two related human CBR enzymes, we analyzed
substrate specificity features of CBR1 and CBR3, and furthermore
establish a structural basis for the activity differences through
mutational, kinetic and crystallographic studies.
Materials and Methods
Cloning and Mutagenesis
A human CBR3 clone was obtained from the MGC clone
collection, and a synthetic, codon-adapted CBR1 clone was
obtained from GenScript Corporation. CBR1 and CBR3
expression constructs were cloned by PCR into pNIC28-Bsa4 or
p11-Bsa4, which are T7/pET21a derived expression vectors
containing Tobacco Etch Virus (TEV) protease cleavable N-
terminal hexahistidine tags. All CBR1 and CBR3 mutants were
generated from the vector template encoding the wild type (WT)
gene by using a site-directed mutagenesis kit (Quick change,
Stratagene). Sequences of all wild-type and mutant constructs were
verified by DNA sequencing.
Expression and purification of CBR proteins
Expression plasmids were transformed into competent Rosetta
E. coli cells. Protein expression was induced at 18uCa ta n
OD600=1 by adding isopropyl-1-thio-b-D-galactopyranoside to a
final concentration of 0.5 mM to cultures grown in Terrific Broth,
supplemented with 50 mg/ml kanamycin or 100 mg/ml ampicillin
at 37uC. Induced cultures were then incubated overnight with
shaking at 18uC. Cell pellets were resuspended in 50 mM HEPES
pH 7.5, 500 mM NaCl, 5 mM imidazole, 5% glycerol and
protease inhibitors (EDTA-free Complete, Sigma). Cells were
lysed using a high pressure homogenizer (EmulsiFlex-C5, Avestin),
followed by centrifugation at 37,000 x g for 45 min.
The supernatant was loaded on an AKTA-Express system (GE/
Amersham) and purified using nickel-affinity chromatography on
a HisTrap FF 1 ml column (GE/Amersham) and gel filtration on
a Superdex 200 column (GE/Amersham) equilibrated in 10 mM
HEPES pH 7.5, 500 mM NaCl, 5% glycerol, 0.5 mM TCEP.
For crystallization purposes, CBR3 wild-type fractions from gel
filtration were subjected to TEV cleavage overnight at 4uC and
the cleaved protein was purified on IMAC-Sepharose (GE/
Amersham). The final step of this purification was ion-exchange
chromatography on a QHP column (GE/Amersham) using a
0.05–2 M NaCl gradient in 50 mM HEPES pH 7.5, 0.5 mM
TCEP, followed by a subsequent buffer-exchange into gel filtration
buffer (as above). All purification steps were analyzed by SDS-
PAGE and the molecular weight of purified protein was verified by
electrospray mass ionization-time-of flight mass spectrometry
(Agilent LC/MSD time-of-flight). Proteins were concentrated to
5–10 mg/ml in an Amicon Ultra-15 concentrator with a 10 kDa
mass cut-off and the final concentration was measured by UV-
spectroscopy (Labtech, Nanodrop 1000 spectrophotometer).
Proteins were flash-frozen in liquid nitrogen until further use.
Substrate screening of CBR1 and CBR3 proteins
Frozen aliquots of CBR1 and CBR3 enzymes were thawed
quickly in water of RT and immediately placed on ice. Assays were
performed at 30uC in buffer S (50 mM sodium phosphate, pH 6.8,
150 mM NaCl, 1 mM MgCl2, 2% (v/v) DMSO). The final assay
solution contained 200 nM of protein, 200 mM NADPH and
200 mM of compound. Prior to the start of the experiment, each
protein was incubated in buffer containing 1 mM NADPH at
1 mM enzyme concentration for 10 minutes at RT. A solution
comprising NADPH in buffer alone was used for the setup of
control experiments for each compound tested. Dilutions of
compounds at 10 mM concentrations in DMSO were prepared in
96-well plates and used to set up the assay plate (384-well white
PCR plate, Bio-rad), by adding 200 nl of each solution into 7.8 ml
of buffer S (STARlet nano, Hamilton). The assay plate was
centrifuged (1 min, 1,000 rpm, RT) to collect all solutions in the
bottom of the wells. Reactions were performed on 24 wells at a
time in a filter-based fluorescence reader (Omega Polarstar, BMG
Labtech). After one minute of monitoring the fluorescence
intensity (excitation, 355 nm; emission, 460 nm) the reactions
were started with injections from the instrument-controlled
syringe, of 2 ml/well of protein/NADPH solution (see above).
The fluorescence intensity in all 24 wells was then monitored for
additional 10 minutes. The next set of reactions were afterwards
automatically started and measured via the instrument’s script
mode until all wells of the plate were read. In total the time for the
measurement of a complete set of triplicates for 96 conditions was
approximately 90 minutes. Data were analyzed for the initial rates
of activity, by regression in the linear region of the curves as
appropriate. Protein-independent, ‘background’ activities were
subtracted and corrected for compound effects, e.g. quenching, by
normalization to the fluorescence offset that resulted from the
injection of NADPH. Specific activities (in mmol/min/mg) were
calculated using the molecular weight of the protein.
Kinetic analysis of CBR proteins
The kinetic measurement for oracin was performed employing a
HPLC method (Agilent 1100 Series, Agilent Technologies,
Waldbronn, Germany). Samples were incubated for 60 min and
reactions were stopped by the addition of 80 ml of 30% ammonia
and cooling on ice. The mixtures were extracted twice with 500 ml
of ethylacetate and the combined organic phases were evaporated
under vacuum. The residue was dissolved in the mobile phase and
analyzed by HPLC (mobile phase, 10 mM hexanesulfonic acid
and 50 mM triethylamine adjusted to pH 3.3 with H3PO4; flow,
1.5 ml/min; 5 mM BDS; Hypersil C18 column (46250 mm,
5 mm, Thermo Electron Corporation, Cheshire, UK)). The
fluorescence emitted at 418 nm was monitored upon 340 nm
excitation. The increase of the product concentration was linear
over the measurement time
Catalytic properties for isatin were determined by measuring
the decrease in absorbance at 340 nm (Cary 100 scan photometer,
Varian, California, USA). A reaction mixture consisted of
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enzyme. The enzyme solution was diluted in the corresponding
elution buffer, a 7:3 mixture of 10:500 (mM) imidazole buffer, to
ensure that substrate consumption was linear over time. Each
concentration was measured at least three times.
The reaction temperature was held constant at 25uC. After a
preincubation time of 2 min 10 ml of enzyme solution were added
to 790 ml of reaction mixture. A reference cuvette contained the
reaction solution without enzyme. Isatin stock solution was
prepared in DMSO. The final concentration of DMSO in the
reaction mixture was 10% (v/v). A maximum of 4000 mM isatin
was used in the kinetic measurement as the change in absorbance
of this concentration still follows Lambert–Beer’s law and no
precipitation of isatin occurred. The kinetic constants were
calculated by nonlinear regression (Gnuplot 4.2) with a molar
extinction coefficient for NADPH of 6.226103 M21c m 21.
For the determination of the kinetic constants for the activity of
the enzymes towards 1,2-naphthoquinone and 1,4-naphthoquinone
a modified version of the protocol used for substrate screening (see
above) was applied: In a 96-well microplate, 12 concentrations of
each substrate, covering ranges from 0 to 4 mM or 0 to 7.5 mM of
1,2- and 1,4-naphthoquinone, respectively, were set up in two rows
and then dispensed into the remaining rows to fill the entire plate.
This was then used as pre-plate for the assay as described above.
The resulting assay concentrations of the two substrates spanned,
thus, ranges from 0 to 1 mM or from 0 to 1.875 mM, respectively.
Linearity in the protein-independent reduction of compound was
observed up to the applied maximum concentrations, thus showing
that the compounds were soluble up to that concentration. The
resulting data were fitted to the Michaelis-Menten equation using
non-linear regression (Levenberg-Marquardt) calculated with
Gnuplot 4.0 (http://www.gnuplot.info) or with Prism 5.0 (Graph-
Pad Software, Inc.). In cases where a fit was not possible, due to a
failure to plateau, a value of kcat/Km was estimated from a linear
regression over the initial part of the curve. Very small activites
(compared to background) were regarded noise below a threshold
for the goodness of fit (R
2) of 0.5 (for all other data values of R
2 were
0.9 or higher)
Crystallization of human CBR3
Frozen protein was quickly thawed, and 5 mM NADP was
added to the protein aliquot prior to crystallization. A sitting drop
consisting of 50 nl of protein solution and 100 nl of well solution
was equilibrated against a well solution containing 1.8 M tri-
ammonium citrate pH 7.0 at 20uC. Large, irregular crystals that
appeared after 24 hrs, were cryo-protected in a mixture of well
solution with 25% glycerol in the presence of NADP before flash-
cooling in liquid nitrogen.
Data Collection, Phasing and Refinement
The native dataset was collected on a Rigaku FRE-Superbright
generator with R-AXIS HTC area detector. Initial phases were
calculated by molecular replacement using the crystal structure of
human CBR1 (PDB 1wma) as a model for PHASER [16]. Before
the refinement commenced, 5% of the data was flagged during
processing for the calculation of Rfree. The final model was created
by alternating rounds of the refinement using REFMAC5 [17] and
model building with adding ligand and solvent molecules using
COOT [18]. The final statistics for the CBR3 binary complex
structure are given in supplementary information Table S2.
CBR3 loop modelling
The active site loop of CBR3 was identified and submitted to a
search against an ICM built-in library containing suitable loops
with matching ends and as close to the sequence as possible. The
algorithm then inserts the matched loops into the model and
modifies the side-chains according to the model sequence. The
next step adjusts the best loops found and keeps a stack of
alternatives. We have manually browsed through the alternatives
until identifying a suitable conformation that satisfied the
condition of being part of the cofactor binding cavity (as seen in
CBR1) and not bearing major atom clashes. The suitable loops
were then submitted to local minimisations, with the side chains
allowed to move along the chi angles in order to solve the
remaining clashes. Upon solution of clashes, the modelled loop
was accepted and the resulting model was saved.
Substrate docking
Docking procedures were performed according to the method-
ology described and implemented in the program ICM v.3.4-
9d[19]. Three different protein structures were used in the docking
procedure as receptors: human CBR1 (PDB 1wma), human CBR3
(PDB 2hrb) and human CBR3 with the active site loop modelled
as a variant of the conformation adopted in human CBR1. Each of
the receptors was docked with seven ligands: 1,2-naphthoquinone,
isatin, oracin, menadione, metyrapone, oxononenal and NNK. In
each docking procedure, grid maps representing different
properties of the receptor were computed. During the docking,
either one of the torsional angles of the ligand was randomly
changed or a pseudo-Brownian move was performed. Each
random change was followed by 100 steps of local conjugate-
gradient minimization against the grid maps. The new conforma-
tion was accepted or rejected according to metropolis criteria using
a temperature of 600 K. The length (number of Monte Carlo
steps) of the docking run as well as the length of local minimization
was determined automatically by an adaptive algorithm, depend-
ing on the size and number of flexible torsions in the ligand. Visual
inspection was performed for the lowest energy conformations
satisfying the absence of clashes after docking.
Results
Substrate screening of CBR3 and comparison to CBR1
Human CBR3 was expressed as N-terminally His6-tagged
protein in E. coli and purified to apparent homogeneity by
consecutive chromatographic steps comprising immobilized metal
affinity and size-exclusion chromatography. The enzyme was
subjected to a substrate screening against a focused library of 111
different carbonyl substrates, using spectrophotometric and
HPLC-based assays. The library consisted of a variety of
endogenous carbonyl containing ligands such as polyols, eicosa-
noids or steroids, as well as a diverse set of xenobiotic carbonyl
compounds, shown to be substrates for distinct types of carbonyl
reductases (for review see [6]).
The screening was carried out side-by-side with human CBR1
under identical conditions and revealed that CBR3 has a much
narrower substrate spectrum compared to CBR1. Our results
confirm the previously recognized broad substrate specificity of
CBR1 [1,3,6,9] which is able to metabolize a wide range of
substrates including endogenous compounds such as prostaglan-
dins or lipid-derived aldehydes, a wide spectrum of xenobiotics
such as ortho- and paraquinones and anthracyclins (supplemen-
tary information Table S1). In total, we found significant activity
(see below, Figure 1) for 43 out of 111 substrates, with a large
fraction of quinones. In contrast, a limited set of substrates were
reduced by CBR3 in an NADPH-dependent manner (31
substrates), usually with significantly less activity than CBR1.
Among the best substrates for CBR3 was 1,2-naphthoquinone, for
Structure of Human CBR3
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to the CBR3 activity for 1,2-naphthoquinone a significant (i.e.,
.10%) activity was observed for 12 out of the 22 tested quinones
(Figure 1). Interestingly, a preference of CBR3 for orthoquinones
is apparent; no activity was found towards menadione, one of the
standard substrates used in activity screens for carbonyl reductases.
This is in line with the lack of activity against any other quinone in
para configuration. Among the non-quinone compounds that were
identified as substrates for CBR3 were isatin and oracin, coniferyl
aldehyde and acetohexamide.
We investigated in more detail the difference in activity between
CBR1 and CBR3 towards important xenobiotics such as isatin
and naphthoquinones (Table 1). The comparison of activities
towards isatin and 1,2-naphthoquinone is in line with the
observation from the screen: CBR1 showed higher catalytic
efficiency for both substrates.
In summary, there are a number of differences between the
activity profiles of the two carbonyl reductases. The most striking
of them is the strong difference in the activity towards the two
naphthoquinones whose only structural difference is the position of
the two carbonyl groups (i.e. para vs. ortho). Furthermore, in
contrast to CBR1 [9,11], CBR3 shows no activity towards
eicosanoids or aliphatic carbonyls like 4-oxononenal. At this point
in time the activity observed against coniferyl aldehyde cannot be
assigned to a specific chemical group, i.e. double bond or carbonyl
group. Further experiments are required to verify product
formation for several of the hits identified.
Active site architecture of CBR enzymes
To understand the substrate specificity differences between
CBR1 and CBR3 we determined the structure of human CBR3 by
X-ray crystallography and compared it to recently determined
human and porcine structures [12,20] of CBR1. Based on these
structures, residues of potential mechanistic importance were
selected for site-directed mutagenetic replacement, and activity of
resulting mutants was tested.
The 3D structures of CBR1 and CBR3 are similar, as expected
with a canonical Rossmann-fold for nucleotide cofactor binding
enzymes of the SDR family [21]. CBRs represent prototypes of
monomeric SDRs with a two-helical insertion stabilizing an
interface that in other SDRs constitutes the main oligomerization
surface (Figure 2).
Inspection of the active sites of the CBR structures reveals an
arrangement consistent with the postulated reaction mechanism
[21,22]. Accordingly, Tyr
193/194 functions as the catalytic acid/
base, Ser
139/140 stabilizes the substrate by forming interactions to
the substrate carbonyl, and Lys
197/198 forms hydrogen bonds with
the nicotinamide ribose moiety, thereby lowering the pKa of the
Tyr-OH to promote proton transfer. Hydride transfer is from the
S-side of C4 of the nicotinamide to the substrate. The role of
Asn
113/114 is to stabilize the position of Lys
197/198 via a conserved
water molecule, and furthermore, to establish a proton relay at the
active site, including coenzyme, substrate, Tyr
193/194, ribose
2’OH, Lys
197/198, water, and Asn
113/114.
The main distinguishing feature of the crystal structures of
human/porcine CBR1 (ternary cofactor inhibitor complex PDB
1wma [12]; binary cofactor complex PDB 1n5d [20]) and human
CBR3 (binary cofactor complex, PDB 2hrb) is the conformation of
the substrate binding loop: whereas the CBR1 structures show a
conformation with a more closed active site, in CBR3 the loop is
engaged in crystal contacts with a symmetry related molecule
(Figures 2A and 2B). Despite extensive crystal screening and
attempts to obtain ternary complexes, we were unsuccessful in
finding different crystal forms. Inspection of the ‘‘open’’ structure
Figure 1. Activity of CBR1 and CBR3 against selected sub-
strates. The threshold for significant activities (measured at 200 mM
substrates and 200 nM (,6.6 mg/ml) enzyme concentration) was set to
10% of the activity of CBR3 against 1,2-naphthoquinone (2.5 mmol/(min
mg)), which was set to 1.0 for comparison. All other activities denoted
either b.t. (below threshold) or n.a. (no activity observed).
doi:10.1371/journal.pone.0007113.g001
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Substrate CBR1 activity CBR3 activity
Km [mM] Vmax [mmol/(min mg)] Km [mM] Vmax [mmol/(min mg)]
1,2-naphthoquinone 310 11 420 6
1,4-naphthoquinone 560 10 n.a.* n.a.*
9,10-phenanthrenequinone 35 9 .80** ,0.1**
isatin 2 2 14630 15
oracin n.d. n.d. 140 0.1
NNK 7500 3 n.a.* n.a.*
*very little activity detected.
**no Michaelis-Menten kinetic observed, value estimated from the slope of linear regression of the relation between activity and substrate concentration.
doi:10.1371/journal.pone.0007113.t001
Figure 2. Structure of human CBR3. Panel A: The substrate binding loop in CBR3 is engaged in contacts (red oval) to a symmetry related copy
(grey), resulting in an open conformation of the active site. The CBR-specific helical insertion involved in dimerization is highlighted in green. Panel
B: Comparison of active site configurations of human CBR enzymes. The overlay of the complex structure of human CBR1 (1wma, in grey) with
cofactor (magenta) and inhibitor (ball and stick model) with the binary complex of human CBR3 with NADP (2hrb, in red) shows the open and closed
active site loop conformations. Panel C: Sequence alignment of human carbonyl reductases CBR1, CBR3 and dicarbonyl reductase DCXR. The 2-
helical insertion found in CBR enzymes is highlighted by green boxing, the active site loop region discussed in this paper is highlighted by a red box.
Secondary structure elements are shown for CBR1 and DCXR below the alignment.
doi:10.1371/journal.pone.0007113.g002
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produce models explaining the observed substrate features. We
therefore decided to model the CBR3 sequence using the CBR1
structure as template (Figure 3), assuming a similar loop
arrangement. The loop modelling results in a conformation with
all residues in acceptable regions of a Ramachandran plot,
moreover docking analysis with different substrates allowed us to
successfully identify critical residues for substrate recognition and
catalysis.A comparisonofthe twoCBRstructuresintheloop-closed
conformationshows a wideopeningto a gorge-like activesite.In the
CBR1-inhibitor complex structure (1wma), the inhibitor molecule
occupies large parts of the entrance and is also covered by a PEG
molecule derived from crystallization. CBR1 has a slightly narrower
substrate binding cleft (Figure 4) than CBR3, mainly as a result of
the terminal sulf-methyl group of Met
141. This residue is replaced in
CBR3 by Gln
142 (Figure 4F), which has a similar but not identical
conformation, as observed in structures 1wma and 2hrb.
Critical residues for quinone specificity in CBR enzymes
Comparison of the active sites of CBR1 and CBR3 suggests that
three residue positions are critical for substrate recognition and
catalysis. In particular, we identified position 229/230 (Trp
229 in
CBR1, Pro
230 in CBR3), position 235/236 (Ala
235 in CBR1,
Asp
236 in CBR3) and position 141/142 (Met
141 in CBR1, Gln
142
in CBR3) as the most likely candidates for determination of
substrate specificity. To analyze the effect of site-directed
mutagenetic replacements on activity differences between the
two enzymes, we selected isatin and two structural quinone
isomers, 1,2- and 1,4-naphthoquinone, as model ortho- and
paraquinone substrates.
A major distinguishing feature between CBR1 and CBR3 is
Trp
229,whichisreplacedbyaprolylresidueinCBR3(cfFigure2C).
The ternary complex of CBR1 with NADP and OH-PP[12], a high
affinity inhibitor, as well as docking studies with different CBR1
substrates suggest a critical role of this residue for substrate
selectivity. As deduced from the CBR1-NADP-1,4-naphthoqui-
none complex model (Figure 5), Trp
229 serves two possible
functions, namely to provide a chemical moiety for aromatic
stacking interactions with the substrate, and also to coordinate a
water molecule through the indole nitrogen. This water molecule
(Wat1), observed in the structure of human CBR1 (PDB 1wma) is
putatively responsible for the CBR1 specificity towards para-
quinones. This seems to be further reinforced by the position of
another water molecule (Wat2) seen in the structure of CBR1,
which matches with the C4-carbonyl group of the pose adopted by
1,4-naphthoquinone docked into the active site of CBR1 (Fig. 5).
We testedthishypothesis,byreplacingTrp
229byProorPhe,aswell
as by creating a double mutant Trp
229Pro/Ala
235Asp.In CBR1 this
second position is located close to Trp
229 as well as to the
nicotinamide and pyrophosphate portions of the cofactor (Figure 3).
Both CBR1 Trp
229 mutants showed significant decrease in activity
for 1,4-naphthoquinone and a modest decrease for its ortho- isomer
(Table 2).Dataforisatin(Table3)showed drasticincreaseinKm for
Trp
229Pro mutant while both Trp
229 substitutions led to faster
substrate turnover highlighting the importance of aromatic stacking
interactions for substrate recognition and binding. Destabilisation
of the active site was much more significant in the Trp
229Pro/
Ala
235Asp double mutant, where CBR1 residues were exchanged
with the corresponding CBR3 residues. It resulted in a 1000-fold
increase in Km and a 50-fold increase in Vmax towards isatin in
comparison to WT CBR1 and in a complete loss of activity towards
1,4-naphthoquinone. Both CBR3 Pro
230 mutants showed some
activitytowardsthepara-naphthoquinonebutdecreasedactivityfor
the ortho-naphthoquinone and isatin, as compared with the WT.
However, the behaviour of the double Pro
230Trp/Asp
326Ala
mutant towards naphthoquinones was very similar to the WT
CBR3 (Table 2), indicating the possible occurrence of a steric clash
between introducedaromatic residue and Asp
236. In case of isatin, a
2-fold decrease in Vmax was observed for the Pro
230Phe mutant,
while replacing Asp
236 with Ala resulted in a significant drop of the
Km value, indicating improved binding of the substrate in the active
site (Table 3). These data suggest that the residues at both positions
are strongly involved in substrate and product binding, indicated by
data with swapped residues that either reduce (CBR1) or increase
(CBR3) catalytic efficiencies. These residues are part of a more
Figure 3. Panel A: Crystal structure of CBR3 (2hrb), close-up of the
activesite.Thecofactor isshownwithitselectrondensity map,contoured
at1s level.Selectedresidues are shown as sticks. Residues involvedinthe
catalysis are shown with white carbon atoms. Residues used for
mutagenesis in this study are shown with yellow carbon atoms. Note
that the active site loop is extended, as found in the crystal structure.
Panel B: Modelled loop in CBR3 (orange) and comparison to CBR1
(green). Positions and residues used for mutagenesis are shown as sticks.
Inhibitor and cofactor from CBR1 (PDB 1wma) are included for reference.
doi:10.1371/journal.pone.0007113.g003
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major role within this proposed network of interactions falls to
Trp
229 in CBR1.
Residues Met
141 and Gln
142, found at homologous positions in
CBR1 and CBR3, respectively (Fig. 2C), and displaying similar
side-chain conformations are located on helix aF and form the
wall opposite of Trp
229/Pro
230 (Figure 3B). Replacing this position
had a dramatic effect on CBR1: while Met
141Gln and Met
141Ala
mutants showed modest decrease in activity towards naphthoqui-
nones (Table 2), combining these mutations with Trp
229Pro led to
destabilisation of the protein (very low solubility, no activity). The
opposite effect was observed for CBR3, with the Gln
142Met
mutant showing a modest increase in activity, and with the double
mutants still active towards 1,2- naphthoquinone.
Taken together, these data highlight the significance of the side-
chain chemistry at position 142 in determination of CBR activity.
Discussion
The objective of this study was to establish a substrate profile for
human CBR3, to compare its enzymatic properties to its paralog
CBR1, and to establish determinants for activity and substrate
specificity. First, CBR3 catalyzes the carbonyl reduction of a much
narrower spectrum of xenobiotic substrates in contrast to the
exceptionally broad substrate profile of CBR1 [1,3,6,9]. Further-
more, no endogenous substrate could be unequivocally detected to
this end for CBR3. Of the known CBR1 substrates, only quinone
compounds with ortho substitutionorcompounds likeisatinand the
cytostatic oracin could be identified as substrates for human CBR3.
Second, this work establishes the structural basis for narrower
substrate specificity in CBR3, and highlights the active site loop
found in CBRs as flexible entity that is one critical factor for
substrate specificity. Exchange of non-conserved residues between
CBR1 and CBR3 in this loop results in position-specific effects
that control catalysis. In particular, the data reveal critical roles for
Trp
229 and Pro
230 in CBR1 and CBR3, respectively, for activity
towards para-quinones. These data suggest that hydrophobic
interactions as well as possible contacts made through a water
molecule coordinated by the indole nitrogen of Trp
229 could
contribute to substrate orientation and possibly product release in
the active site. This is supported by the fact, that in the
experimental structures, the main-chain of the loop starts to
deviate at position 229. This clearly indicates that a major
difference between CBR1 and CBR3 is a large, hydrophobic wall
built by Trp
229 in CBR1, and a more open substrate site in CBR3,
irrespective if the loop modelling, as performed in this work, is
correct or not. Other variable residues found on the loop also
contribute to a varying extent to substrate specificity, such as
Figure 4. Comparison of active site properties of human CBR1 and CBR3. A–C: CBR1 (green), D–E: CBR3, with modelled loop
(orange). First Column (A and D): solvent accessible surface representation of the active site pockets coloured according to electrostatic potentials,
with the cofactor represented as sticks. Yellow line marks the plane cutting through the active site. The plane divides the pocket into two halves that
are depicted in the following two columns. Second column (B and E): ‘left’ half of the pocket. Third column (C and F): ‘right’ half of the pocket.
Cofactor is shown for orientation purpose. Residues that were mutated in this study are marked with asterisks. Catalytic residue labels are underlined.
doi:10.1371/journal.pone.0007113.g004
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236 in CBR3, introducing an additional charge into the
active site in comparison to CBR1. Other determinants for activity
are residues found at position 141/142, namely Met
141 in CBR1
and Gln
142 in CBR3. Although of similar size, these residues have
significant differential effects on catalytic properties of the active
site. A preliminary study [23] showed the whole region
encompassing residues 235/236–243/244 as crucial in determi-
nation of activities of CBR1 and CBR3. Replacing this region in
CBR3 with residues from CBR1, combined with Pro
230Trp
mutation, was sufficient for a 1000-fold increase in activity to
,40% of activity of CBR1. To summarise, the substrate pockets of
CBR1 and CBR3 show fundamental differences in size, as
manifested through residues found at position 229, as well as in
surface properties, as seen with the more polar residues lining the
active site in CBR3 (Figure 4).
Although not specifically tested in this study, it is conceivable that
some of the activities observed in this study are related to
‘‘propinquity’’ effects [24]. It has been previously shown that
orthoquinones can be reduced to the corresponding hydroquinones
in a manner not involving a protein derived catalytic base, as seen
withmutantstudiesperformedonmembers ofthe aldo-keto reductase
[24] or medium-chain dehydrogenase/reductase (MDR) families
[25]. Instead, the enzyme is used as a ‘‘scaffold’’ to bring the reduced
nicotinamide cofactor and the orthoquinone into close proximity, to
allow hydride and direct solvent proton transfer to the adjacent
carbonyl groups [24]. This possibility underlines the importance of
correct cofactor and substrate positioning in the active site.
As observed from in silico screening (http://www.genecards)
and other experimental data [15], CBR1 is an ubiquitously
expressed enzyme with highest levels found in liver and the central
nervous system, with a significantly lower transcription level but
overlapping expression pattern found for CBR3. This suggests
some redundancy in substrate specificity, but could also point to
different substrates classes and hence different roles for these
paralogous enzymes. CBR1 plays without doubt a major role in
the phase I metabolism of xenobiotic compounds including
xenobiotic quinones [1,3,6,26], a function which we at present
cannot wholeheartedly postulate for CBR3, in light of the
observed narrow substrate spectrum. In addition, several more
recently conducted studies also suggest a critical role for CBR1 in
the metabolism of endogenous lipid mediators such as prostaglan-
dins or lipid oxidation products such as the highly reactive and
genotoxic 4-oxonon-2-enal, which is produced under oxidative
stress [27–29]. This could relate the observations that CBR1 is
involved in metastasis, neurodegeneration and apoptosis to its
properties to catalyze prostaglandin and lipid aldehyde inactiva-
tion [9,11,27], however, final experimental proof for this
hypothesis is necessary. In light of these data, the structural
differences determined, and the apparent lack of activity of CBR3
towards lipid mediators like prostaglandins or oxononenal we
suggest that CBR3 is likely involved in the metabolism of
structurally and chemically different substrates. The precise
identity of these compounds needs to be established in further
metabolomic and molecular genetic studies.
Figure 5. Active site of human CBR1 with 1,4-naphthoquinone
docked into a catalytically competent orientation (the water
molecules Wat1 and Wat2 were present in the crystal structure
of CBR1, but were not used in the docking). The catalytic residues
Ser139 and Tyr194 orient the substrate carbonyl, whereas residue
Trp229 makes aromatic-stacking interactions and coordination of a
water molecule (Wat1) through the indole nitrogen. As a result, the
water Wat1 is positioned to form hydrogen bond with the carbonyl
group in position to the substrate carbonyl. Note the crystallographic
water molecule Wat2 found in the same position as the carbonyl
oxygen from the docked substrate. Distances are shown in A ˚.
doi:10.1371/journal.pone.0007113.g005
Table 2. Relative catalytic efficiency (kcat/Km) of CBR1/CBR3 mutants and wild-type proteins against naphthoquinone substrates.
CBR1
1,2-naphthoqui-none
[ortho-]
1,4-naphthoqui-none
[para-] CBR3
1,2-naphthoqui-none
[ortho-]
1,4-naphthoqui-none
[para-]
WT 13.3 6.4 WT 1.0 ,0.1
W
229F 10.4 2.1 P
230F 0.3 0.3
W
229P 8.8 0.5 P
230W 0.2 0.2
W
229P/A
235D1 . 5 ,0.1 P
230W/D
236A 0.7 0.1
W
229P/M
141A n.d.* n.d.* P
230W/Q
142A0 . 4 ,0.1
W
229P/M
141Q n.d.* n.d.* P
230W/Q
142M0 . 7 ,0.1
M
141Q 9.7 3.5 Q
142M 1.2 0.3
M
141A 8.5 1.8 D
236A ,0.1 0.1
Catalytic efficiency of WT CBR3 against 1,2-naphthoquinone was set to 1.0 for comparison.
*protein unstable.
doi:10.1371/journal.pone.0007113.t002
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Table S1 Activity screening of human CBR1 and CBR3 against
the compounds in the focused carbonyl substrate library. Only
activities above 0.25 mmol/(min mg), i.e. above 10% of the activity
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